DCM
BMRN icon

Difesa Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Difesa Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,250
Closed -$802K – 6
2023
Q2 		$802K Sell
9,250
-2,200
-19% -$207K 2.11% 14
2023
Q1 		$1.11M Buy
11,450
+450
+4% +$46.7K 0.73% 44
2022
Q4 		$1.14M Buy
11,000
+8,000
+267% +$751K 0.88% 52
2022
Q3 		$254K Buy
3,000
+250
+9% +$22.3K 0.13% 92
2022
Q2 		$228K Buy
+2,750
New +$219K 0.13% 96

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Difesa Capital Management's BMRN Position: Q3 2023 in Review

Difesa Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 9,250 shares — an estimated $802K sold.

Difesa Capital Management first reported a position in BMRN in Q2 2022 and held it in 5 quarters. The position peaked at $1.14M in Q4 2022. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Difesa Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Difesa Capital Management sold 9,250 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $802K.
  • Difesa Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Difesa Capital Management's BioMarin Pharmaceuticals position peaked at $1.14M in Q4 2022.
  • 520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.